Details

Autor(en) / Beteiligte

• Rosenfeld, Philip J
• Brown, David M
• Heier, Jeffrey S
• Boyer, David S
• Kaiser, Peter K
• Chung, Carol Y
• Kim, Robert Y

Titel

Ranibizumab for Neovascular Age-Related Macular Degeneration

Ist Teil von

• The New England journal of medicine, 2006-10, Vol.355 (14), p.1419-1431

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2006

Quelle

MEDLINE

Beschreibungen/Notizen

• Previous studies have suggested that targeting intravitreal vascular endothelial growth factor A (VEGF-A) counters choroidal neovascularization and hence age-related macular degeneration. A double-blind, placebo-controlled trial of ranibizumab, which neutralizes all isoforms of VEGF-A, for treatment of minimally classic and occult age-related macular degeneration retarded the progression of the disease and improved visual acuity in some patients. For the treatment of minimally classic and occult age-related macular degeneration, ranibizumab retarded the progression of the disease and improved visual acuity in some patients. Age-related macular degeneration is a leading cause of irreversible blindness among people who are 50 years of age or older in the developed world. 1 – 3 The neovascular form of the disease usually causes severe vision loss and is characterized by the abnormal growth of new blood vessels under or within the macula, the central portion of the retina responsible for high-resolution vision. Neovascularization in this disease is classified by fluorescein angiography into major angiographic patterns termed classic and occult, which may be associated with various degrees of aggressiveness of disease, vision loss, and response to various treatment options. 4 Pharmacologic therapies . . .